Drug Information

Drug General Information
Drug ID
D0YA0N
Former ID
DCL000729
Drug Name
BR3-Fc
Indication Rheumatold arthritis; Idiopathic thrombocytopenic purpura [ICD9: 287.31, 710-719, 714; ICD10:D69.3, M00-M25, M05-M06] Discontinued in Phase 2 [536737]
Company
Genentech; Biogen Idec
Target and Pathway
Target(s) Tumor necrosis factor ligand superfamily member 13B Target Info Inhibitor [536651], [536737]
KEGG Pathway Cytokine-cytokine receptor interaction
NF-kappa B signaling pathway
Intestinal immune network for IgA production
Rheumatoid arthritis
Reactome TNFR2 non-canonical NF-kB pathway
TNFs bind their physiological receptors
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
WikiPathways Spinal Cord Injury
References
Ref 536737Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
Ref 536651Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
Ref 536737Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.